Navigation Links
Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatism's Congress
Date:6/8/2011

NEW YORK, June 8, 2011 /PRNewswire/ -- One of the major annual rheumatology conferences, the European League Against Rheumatism's Congress (EULAR), was held May 25-28 in London.  Citeline, Inc., reviewed the trends and highlights from clinical trial results reported at EULAR, noting that approved biologics in rheumatoid arthritis dominated the program, comprising roughly 25% of clinical trial abstracts presented.  

Updates from long-term trials for approved biologics in RA—including adalimumab, etanercept, abatacept, rituximab and tocilizumab—provided further evidence of sustained clinical efficacy by standard measures, but also extended to reductions in joint damage (by radiographic and MRI methodologies), remission induction and effective treatment of early disease.  Of these approved biologics, tocilizumab trial results were the most numerous, and included several reports of treatment impact on serum lipid levels and other cardiovascular-related outcomes.  

Citeline's Senior Analyst in Autoimmune/Inflammation, Claire Herman, noted that the industry-wide interest in personalized medicine was evident at EULAR, with an array of abstracts presenting results from studies aimed at identifying biomarkers and pharmacogenomic markers as predictors of response to specific approved biologics. "This research is indicative of companies' focus on carving out individual niches within this highly competitive chronic disease arena," remarks Ms. Herman.  

Additionally, a number of these approved drugs' sponsors continue to focus on life-cycle management and expanded labeling, as evidenced by abstracts reporting results from trials of the subcutaneous formulation of abatacept (ALLOW and ACQUIRE), pivotal trials for Japanese approval of golimumab for RA, tocilizumab juvenile RA studies (TENDER), and rituximab combination therapies results. Trends in Trials for Approved Biologic Therapies in Rheumatoid ArthritisNumber of ab
'/>"/>

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 The ... the five years to 2014. Industry operators were able ... during the period, as well as establish distribution contracts ... due in large part to its novelty; energy drinks ... in that time, industry operators have been able to ...
(Date:9/19/2014)... 2013 NEXT Award-winning technology consultancy ... for the 2014 NEXT Awards in the Technology ... has been selected as the sole female finalist ... Chamber of Commerce and the Nashville Entrepreneur Center ... accomplishments of companies and individual entrepreneurs in five ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Buoyed by technological advancements, surgical techniques, and ... become the preferred treatment for several chronic diseases ... liver. Advancements in organ and tissue transplantation have ... patients. Organ transplant today represents a ...
(Date:9/19/2014)... researchers at the University of Utah School of Medicine ... of mitochondria in debilitating and fatal motor neuron diseases ... such illnesses. , Researchers led ... when healthy, functioning mitochondria was prevented from moving along ... neurons mice developed symptoms of neurodegenerative diseases. In ...
(Date:9/19/2014)... grow well in infertile land, and bear many beans ... is because most legumes have a symbiotic relationship with ... air and then supply the host plant with ammonia ... organs called nodules in their roots. However, if too ... the growth of the plants, because the energy cost ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 2Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 3Health News:Long-distance communication from leaves to roots 2
... June 29 Medicsight PLC, a subsidiary of MGT Capital ... industry leader in the development of Computer-Aided Detection (CAD) and ... of disease, is pleased to announce the launch of its ... benefits of Medicsight,s ColonCAD software truly accessible to all radiologists ...
... , LONDON, June 29 The Healthcare Group at ... Quarterly Analyst Briefing Presentation on the European Hospital Information Systems ... at 2 p.m. GMT. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ... some kind of information system in place, only a few ...
... Clarient, Inc. (Nasdaq: ... services resource for pathologists, oncologists and the pharmaceutical industry, today announced ... Index when Russell Investments reconstitutes its comprehensive set of U.S. and ... of additions posted June 12 on www.russell.com . ...
... ... your pet healthy and happy and is more likely to avoid serious and costly health problems ... ... health care can prevent expensive vet bills in the future, pet owners are reminded, as everyone continues ...
... Florida,s First Certified Urgent ... County Florida has become the first in the State to receive formal recognition as a Certified ... ... Care Medical Centers of Palm Beach County Florida has become the first in the State to ...
... ... to access critical health data stored in electronic health records (EHRs). The company has just ... , ... 29, 2009 -- Orion Health , a market leader in providing clinical workflow and ...
Cached Medicine News:Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 2Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 3Health News:Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care Value 2Health News:Clarient Set to Join Russell 3000 Index 2Health News:Clarient Set to Join Russell 3000 Index 3Health News:Clarient Set to Join Russell 3000 Index 4Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 2Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 3Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 3Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 2Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 3
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner....
The soft tip sheath design for smooth delivery and retrieval of Constellation advanced mapping basket catheters....
Fast-Cath, Maximum, Maximum Xtra, and Maximum ACT introducers represent the largest line of standard and specialty hemostasis introducers in the world....
Medicine Products: